pMD2.G, and packaging plasmid pCMV ⌬ R8.91 were kindly provided by Dr. Dider Trono (Lausanne, Switzerland). Goat polyclonal antibody to human apoE was purchased from Millipore (Billerica, MA). Rabbit polyclonal antibody to LRP1, rat anti-Ly6C biotin, and ELISA kits for human apoE were purchased from Abcam Inc. (Cambridge, MA). Rabbit anti-CCR2 was purchased from BD Biosciences (San Jose, CA). HRP-conjugated rabbit anti-goat and goat anti-rabbit IgG antibodies were purchased from Sigma (St. Louis, MO). Rabbit polyAb anti-arginase I was purchased from Genetex (Irvine, CA). Rabbit polyAb anti-arginase II was purchased from Proteintech Group, Inc. (Manchester, UK). Rat antimouse F4/80 antibody and rat anti-mouse CD68 biotin were purchased from AbD Serotec (Raleigh, NC) and peroxidase-anti rat antibody was purchased from Vector Labs (Burlingame, CA). The mammalian transfection system was purchased from Promega (Madison, WI). Cholesterol reagent with standard was purchased from RAICHEM (San Marcos, CA). Superose 6 column was purchased from GE Health Care Life Sciences (Pittsburg, PA).
Mice
The male apoE Ϫ / Ϫ mice used as recipients for bone marrow transplant (BMT) were obtained from the Jackson Laboratory (Bar Harbor, ME) and were 12 weeks of age when used. The male apoE
/LDLR Ϫ / Ϫ DKO mice were bred in house and were used at 8 weeks of age. Mice were kept on a chow diet throughout the experiment. All animal experiments were carried out in compliance with National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees of Vanderbilt University and Oregon Health and Science University.
Macrophage cholesterol effl ux
apoE Ϫ / Ϫ macrophages were transduced in 24-well plates with apoE2, apoE3, or apoE Sendai and left to recover for 24 h. Cells were loaded with 100 g/ml of 3 H-cholesterol-acetylated LDL for 48 h. Subsequently, cells were incubated for 1 h with 0.1% BSA DMEM to allow internalization of membrane-bound acetylated LDL. Then, DMEM containing 10 g/ml of recombinant apoA-I (as acceptor) was added and cells were further incubated for 24 h. Medium was removed and cells were washed twice with PBS before collection in isopropanol. 3 H radioactivity in the effl ux medium and cell extracts was counted using a Beckman LS6500 liquid scintillation counter (Palo Alto, CA).
BMT
BMT-recipient mice were maintained on antibiotic water containing 100 mg/l neomycin and 10 mg/l polymyxin B for 7 days before and 14 days after transplantation. Four hours before transplantation, recipient mice were lethally irradiated with 900 rads from a cesium ␥ source. Bone marrow was harvested from femurs and tibias of donor mice by fl ushing with RPMI medium 1640 supplemented with 2% fetal bovine serum and heparin (5 units/ml). Bone marrow cells were washed, resuspended in fresh media, and counted. Bone marrow cells were transduced with lentiviral vector containing green fl uorescent protein (GFP), apoE2, apoE3, or apoE Sendai as previously described ( 16 ) . Lethally irradiated recipients received 5 × 10 6 transduced bone marrow cells in 200 l by retro-orbital injection.
Serum cholesterol determinations
Nonfasting mice were anesthetized with methoxyfl urane and blood was collected by retro-orbital venous plexus puncture. Serum cholesterol determinations were performed using the cholesterol reagent kit from RAICHEM. In brief, serum was diluted 1:100 in sterile water, and a 100 l aliquot was loaded on the microplate well and mixed with 100 l of freshly prepared cholesterol reagent. the glomeruli, with subsequent glomerulosclerosis, glomerular loss, and possible progression to chronic renal failure ( 20, 21 ) . Several rare apoE mutations have been linked to the development of LPG ( 22 ) , with the most common and best characterized being apoE Sendai ( 23 ) . The apoE Sendai protein carries a missense mutation of Arg-to-Pro substitution at position 145 (R145P) within the receptor binding domain of apoE ( 24 ) . apoE Sendai has the charge of apoE2 and the isoform structure of apoE3 (Cys112, Arg158). LPG patients carrying apoE Sendai may show a lipoprotein profi le ranging from near normal to one that resembles type III hyperlipoproteinemia (24) (25) (26) . Two case studies and one small population study showed that lipid-lowering therapies are linked to improved renal status in LPG patients (27) (28) (29) .
Although the apoE Sendai mutation has been directly linked to LPG (30) (31) (32) (33) , the pathogenesis of the disease is not defi ned. It has been postulated that the ␣ -helix-breaking proline residue in apoE Sendai induces conformational changes that also generate a novel binding domain with affi nity for specifi c glomerular glycoproteins, leading to the extracellular accumulation of lipoproteins in the renal mesangium ( 34 ) . The pathogenetic role of apoE Sendai in LPG has been proven with the replication of an experimental LPG phenotype in mice after adenovirus-driven expression of apoE Sendai ( 30 ) . Although its mutation is in the receptor binding domain, apoE Sendai is capable of effi cient lipoprotein clearance, and its expression decreases serum cholesterol levels in apoE Ϫ / Ϫ mice ( 30 ) . In addition, apoE Sendai is more effective than apoE2 in binding to HSPG ( 34 ) . Thus, there is a potential for this protein to exert a benefi cial effect on the vasculature while causing renal disease. Macrophage expression of apoE infl uences both serum lipids and atherogenesis ( 11 ) . Because macrophages play a role in glomerular disease ( 35, 36 ) , we set out to study whether expression of apoE Sendai from macrophages is suffi cient to recreate the LPG phenotype in the mouse, and to determine simultaneous changes in aortic and renal status in hyperlipidemic mice expressing this apoE mutant. Through bone marrow transplantation, we produced two types of chimeric mice expressing apoE exclusively from macrophages: 1 ) apoE Ϫ / Ϫ mice, whose dyslipidemia is corrected by apoE expression; and 2 ) apoE Ϫ / Ϫ /LDLR Ϫ / Ϫ double KO (DKO) mice, whose dyslipidemia is not affected by apoE expression ( 15, 37 ) . Our results support a scenario where the expression of macrophage apoE Sendai protects against atherosclerosis, irrespective of serum lipid changes, while causing glomerular changes compatible with LPG under hyperlipidemic conditions.
apoE Sendai protects against atherosclerosis and promotes LPG was detected by use of a mixture of luminol, p-coumaric acid, and hydrogen peroxide in 100 mM Tris (pH 8.5).
Histochemistry studies of renal sections
At the end of the experiment, mice were euthanized and their kidneys harvested and fi xed in 4% paraformaldehyde for paraffi n sections. Paraffi n serial sections (3 m) were stained with periodic acid schiff (PAS) and Jones for renal injury assessment. The O'Brien Center Renal Histology Core Laboratory at Vanderbilt University Medical Center completed all renal histology. Injury was assessed semi-quantitatively on a 0-3+ scale, with minimal injury (0.5), mild injury (1+), moderate injury (2+), and moderate to severe injury (3+). Renal sections were assessed for mesangial expansion, mesangiolysis, tubular injury, and vacuoles. Paraffi n sections were also stained using rat anti-mouse F4/80 for detection of renal macrophages. Macrophage levels are presented as number of F4/80-positive cells per high power fi eld.
Statistical analyses
GraphPad Prism 6 software was used to carry out statistical analyses. The Mann-Whitney test was used to compare atherosclerosis data of two groups. The Student's t -test was used for comparison between two groups for all other analyses. ANOVA with post hoc Tukey's multiple comparison test was used when more than two groups were compared. Results are presented as mean ± standard deviation or percent ± coeffi cient of variance. Differences from the GFPtransduced group were reported as P < 0.05 (a), P < 0.01 (b), and P < 0.001 (c). Differences from the apoE2-transduced group were reported as P < 0.05 (d) and P < 0.01 (e). No statistical signifi cance was found between apoE3 and apoE Sendai in any of the experiments.
RESULTS

Expression of apoE Sendai in cells
Bone marrow cells from 8-week-old apoE Ϫ / Ϫ mice were transduced either with GFP (control), apoE2, apoE3, or apoE Sendai lentiviral constructs ( Fig. 1A ) . apoE2, apoE3, and apoE Sendai were expressed in similar levels by the cells After 10 min incubation at 37°C, absorbance at 490 nm was measured on a Molecular Devices microplate reader. Cholesterol levels on chromatography fractions were determined similarly, except that 100 l from each tube was loaded directly into the microplate well and mixed 1:1 with the cholesterol reagent. Mouse lipoproteins were separated from serum by size exclusion chromatography [fast protein LC (FPLC)] using a Superose 6 column on a FPLC system with a Model 500 pump from Waters (Milford, MA), commonly used in our laboratory ( 38 ) . In short, a 100 l aliquot of mouse serum was injected into the column and separated with a buffer (0.15 M NaCl, 0.01 M Na 2 HPO 4 , and 0.1 mM EDTA) at a fl ow rate of 0.5 ml/min. Forty fractions of 0.5 ml each were collected with the lipoproteins being contained within. Fractions 15-19 were VLDLs and chylomicrons; fractions 20-26 were IDLs, LDLs, and large HDLs; fractions 27-33 were HDLs; and fractions 34-40 were lipoprotein-defi cient serum.
Analysis and quantitation of arterial lesions
At the end of the experiment, mice were euthanized and their hearts were fl ushed with saline, embedded in OCT, and snap-frozen in dry ice. The inferior vena cava was cut to allow the perfusate to exit. Frozen sections of 10 m thickness were taken in the region of the proximal aorta starting from the end of the aortic sinus and for 300 m distally, according to the technique of Paigen et al. ( 39 ) . Sections were stained with Oil Red O (ORO) and counterstained with hematoxylin. Quantitative analysis of lipid-stained lesions was performed on sections starting just beyond the end of the aortic sinus. The lipid-stained lesions were measured by digitizing morphometry and reported in square microns per lesion . For immunostaining, sections of 5 m thickness were taken in the region of the proximal aorta starting from the end of the aortic sinus.
Immunoprecipitation and Western blotting
Transduced mouse peritoneal macrophage cell lysate was coimmunoprecipitated with goat anti-apoE antibody using protein-A magnetic beads, as recommended by the manufacturer. Samples were loaded onto 4-12% Bis-Tris precast gels for electrophoresis. The proteins were then transferred to nitrocellulose membranes. Rabbit anti-LRP1 primary and anti-rabbit HRP-conjugated secondary antibodies or goat anti-apoE primary and anti-goat HRP-conjugated secondary antibodies were used to detect target proteins. Signal Supplemental Material can be found at:
peak (AUC = 219) compared with apoE2 recipients (AUC = 191 and 268, respectively). GFP-and apoE3-recipient mice show the expected lipoprotein profi les. No differences in body weight were seen between groups (data not shown).
Effects on proximal aorta lesion size and composition
Eight weeks after BMT, mice were euthanized and a quantitative analysis of the extent of aortic atherosclerosis, using ORO-stained sections of the proximal aorta, was performed. The mean aortic lesion area of apoE2-recipient mice (n = 10) was 23% lower (183,847 ± 44,446 um 2 ) than that of control mice (n = 7) expressing GFP (239,007 ± 69,446 um 2 ). In apoE3-(n = 5) and apoE Sendai -recipient mice (n = 11), lesions were signifi cantly smaller compared with GFP-and apoE2-recipient mice (lesion area 105,095 ± 15,274 m 2 and 124,849 ± 34,696 m 2 , respectively) ( Fig. 3A ) . No differences were noted in extent of lesion areas in apoE3 versus apoE Sendai mice ( Fig. 3A ) . Representative ORO-stained sections of the proximal aorta are shown in supplementary Fig. I . Lesion composition analyses showed that apoE3-and apoE Sendai -recipient mice also had significantly fewer Ly6C-positive cells (2.3 ± 0.5% and 2.1 ± 0.3%, respectively) compared with apoE2-recipient mice (2.9 ± 0.3%) or GFP recipients (3.6 ± 0.6%), as shown in Fig. 3B . Similar results were also found in CCR2-positive cells in the atheroma (supplementary Fig. IIA) . The M1/M2 ratio in lesional macrophages (arginase II/arginase I in CD68-positive cells) was similar between groups (supplementary Fig. IIB) . No differences were seen in cholesterol effl ux from apoE Ϫ / Ϫ macrophages transduced with apoE2, apoE3, or apoE Sendai (supplementary Fig. IIC ).
Renal changes in apoE
Ϫ / Ϫ mice after BMT apoE Sendai is directly related to LPG etiology in humans and mice ( 24, (30) (31) (32) (33) . Kidney sections were assessed after ( Fig. 1B ) . Figure 1C shows that macrophages retain the apoE2 isoform, but not apoE3 and apoE Sendai . We have previously reported intracellular retention of apoE2 in macrophages due to its interaction with LRP1 ( 9 ) . Here, we show that apoE Sendai is weakly associated with LRP1 and is not retained in macrophages. To further test to determine whether the lack of cellular retention of apoE Sendai (Cys112, Arg158) is due to its mutation in the ligand-binding domain (R145P), we have generated an artifi cial "Sendailike" mutation by inserting the ligand-binding domain mutation R145P on an apoE2 isoform (Cys112, Cys158). Figure 1C shows that, similarly to apoE Sendai , the apoE2-R145P artifi cial mutation had impaired interaction with LRP1 and was not retained by the cells.
Effects on serum lipid levels
After lethal irradiation, 12-week-old male apoE Ϫ / Ϫ mice were transplanted with 5 × 10 6 bone marrow cells expressing GFP, apoE2, apoE3, or apoE Sendai. Eight weeks after BMT, macrophage apoE expression resulted in a decrease in serum cholesterol levels. apoE2-, apoE3-, and apoE Sendai -recipient mice all had signifi cantly lower cholesterol (333 ± 62 mg/dl, 183 ± 62 mg/dl, and 259 ± 41 mg/dl, respectively) compared with control GFP recipients (432 ± 63 mg/dl) ( Fig. 2A ) . apoE3-and apoE Sendairecipient mice, postBMT, had cholesterol levels signifi cantly lower compared with apoE2 recipients. Cholesterol levels of apoE3-recipient mice were lower compared with apo-E Sendai , but did not reach statistical signifi cance. Size exclusion chromatography analyses ( Fig. 2B ) show the difference in chylomicron-remnant/VLDL cholesterol, LDL cholesterol, and HDL cholesterol peaks between the groups. Interestingly, both apoE2 and apoE Sendai show a partially corrected lipoprotein profi le, with apoE Sendai having a lower chylomicron-remnant/VLDL cholesterol peak [area under the curve (AUC) = 154] and LDL cholesterol ( Fig. 5A ). Rep resen tative sections of the proximal aorta are shown in supplementary Fig. V . Lesion composition analyses showed that DKO apoE Sendai -recipient mice also had signifi cantly fewer Ly6C-positive cells (5.5 ± 1.1%) compared with DKO mice recipient of apoE2 (7.8 ± 1.2%) ( Fig. 5B ) . Similar results were also found in CCR2-positive cells in the atheroma (supplementary Fig. VIA) . The M1/M2 ratio in lesional macrophages (arginase II/arginase I in CD68-positive cells) was similar between groups (supplementary Fig. VIB) .
Renal changes. We further tested macrophage apoE Sendai effects on glomerular integrity under hypercholesterolemic conditions in DKO mice. apoE Ϫ / Ϫ and DKO mice have been reported to develop renal abnormalities that are different from those found in LPG (40) (41) (42) . The effect of apoE Sendai on renal pathology under hyperlipidemic conditions was assessed in DKO apoE2-and apoE Sendai -recipient mice by a blinded expert pathologist, as reported above. Glomeruli of DKO apoE2-recipient mice had minimal increase in mesangial matrix and a glomerular injury score of 1+, whereas DKO apoE Sendai recipients had smaller glomeruli and increased mesangial matrix with focal mesangiolysis ( Fig. 6 ) , and a glomerular injury score of 2+ to 3 ( Table 2 ). Glomeruli from DKO mice recipient of apoESendai also PAS and Jones staining. Our blinded-operator semiquantitative evaluations showed a lower average glomerular injury score in apoE Sendai recipients (average score 0.5 on a 0 to 3+ scale) compared with both GFP-(average score 1 to 2+) and apoE2-recipient mice (average score 2+) ( Table 1 ). Although mesangial matrix increase was seen in some glomeruli in all groups, none of the glomeruli contained actual LPG-like lesions ( Fig. 4 ) . Similar amounts and distribution of vacuoles were seen in the proximal tubules in all groups, with an average injury score of 2 to 3+ in GFP-recipient mice and 2+ in apoE2 and apoE Sendai recipients, as shown in Table 1 . No renal artery atherosclerosis was seen in any of the groups ( Fig. 4 ) . Glomerular and tubular lipid distribution (ORO staining) was also assessed, showing lipid accumulation in accordance with the injury score (supplementary Table I ). No differences were found in the percent of macrophages (F4/80-positive cells) in the kidney and no macrophages were present in glomeruli in any of the groups (supplementary Fig. IIIA and B, respectively). shown that expression of apoE in this model does not reduce serum lipid levels, and that macrophage-expressed apoE can protect against atherosclerosis, even in the absence of cholesterol changes ( 15, 37 ) . Therefore, we set out to study the effect of macrophages expressing apoE Sendai compared with apoE2 on the atheroma . As expected, we did not fi nd differences in serum cholesterol levels in either group (supplementary Fig. IVA) . We have previously reported that serum clearance of macrophage apoE is altered in these DKO mice resulting in accumulation of circulating apoE ( 15 ) . Similarly, 8 weeks after BMT, serum apoE levels in DKO recipients were signifi cantly higher compared with apoE Ϫ / Ϫ recipient mice, both in apoE2-(3.4-fold) and apoE Sendai -recipient mice (2.8-fold) (supplementary Fig. IVB) . Despite similar cholesterol and serum apoE levels in DKO recipients, quantitative analysis of atherosclerosis in the proximal aorta showed a signifi cant 18% decrease in aortic lesion size of apoE Sendai -recipient in the artery wall (protection against atherosclerosis) and the kidney (promotion of LPG). Here, we investigated whether expression of apoE Sendai from macrophages causes LPG and infl uences atherosclerosis under conditions of either modest or extreme dyslipidemia, and with varying degrees of apoE accumulation in serum. Our results support a novel biologic scenario where macrophage expression of apoE Sendai reduces arterial wall infl ammation, suppresses atherosclerosis, and at the same time induces glomerular deterioration under severe hyperlipidemia. The goal of our study was to investigate the simultaneous effects of macrophage apoE Sendai expression, compared with those of the common isoforms, apoE2 and apoE3, on the aorta and glomeruli of mice under different hyperlipidemic conditions. Glomerulosclerosis and atherosclerosis share common mechanisms. For example, chronic infl ammation is a critical element of both atherosclerosis ( 44, 45 ) and glomerular disease ( 46, 47 ) . In addition, macrophages are involved in both processes ( 48, 49 ) , and renal disease greatly increases cardiovascular risk ( 50 ) . We and others have shown that macrophage-derived apoE accounts for only 10% of total circulating levels, yet this amount is sufficient to normalize lipoprotein levels and to protect against atherosclerosis ( 11, 13, 15 ) . In this study, apoE Ϫ / Ϫ recipient mouse serum levels reached ‫ف‬ 15% of normal physiological levels, whereas DKO reconstituted mice were 3-fold higher ( ‫ف‬ 45% of normal physiological level). Macrophage showed lipid thrombi fi lling the capillary loop, similar to the histological fi nding in human LPG ( Fig. 6 ). Both groups showed vacuoles in the proximal tubules, with an average tubular injury score of 2+. Lipid staining showed increased lipid accumulation in the glomeruli and tubules of apoE Sendai -recipient mice compared with apoE2-recipient mice (supplementary Table II ). Finally, we found no changes in the percent of renal macrophages (F4/80-positive cells), and no macrophages were present in either normal (apoE2 recipients) or injured (apoE Sendai recipients) glomeruli (supplementary Fig. VIIA and B, respectively).
Effects in apoE
GFP → apoE Ϫ / Ϫ #1 1+ 2-3+ GFP → apoE Ϫ / Ϫ #2 2+ 2-3+ GFP → apoE Ϫ / Ϫ #3 2+ 2-3+ GFP → apoE Ϫ / Ϫ #4 2+ 2-3+ GFP → apoE Ϫ / Ϫ #5 2+ 2-3+ apoE2 → apoE Ϫ / Ϫ #1 2+ 2+ apoE2 → apoE Ϫ / Ϫ #2 2+ 2+ apoE2 → apoE Ϫ / Ϫ #3 2+ 2+ apoE2 → apoE Ϫ / Ϫ #4 2+ 2+ apoE Sendai → apoE Ϫ / Ϫ #1 0.5 1-2+ apoE Sendai → apoE Ϫ / Ϫ #2 0.5 2+ apoE Sendai → apoE Ϫ / Ϫ #3 0.5 2-3+ apoE Sendai → apoE Ϫ / Ϫ #4 0.5 2-3+ apoE Sendai → apoE Ϫ / Ϫ #5 0.5 2+
DISCUSSION
Bone marrow transplantation is a reliable and validated approach to study the effect of changes in macrophage gene expression on atherosclerosis in the mouse ( 2, 11 ) . apoE was the fi rst apoprotein studied in murine BMT experiments, and has been shown to affect atherosclerosis both by reducing serum lipid levels ( 11 ) and by exerting local benefi cial effects in the forming atheroma ( 43 ) . Several very rare apoE mutants are associated with a progressive glomerular disease, termed LPG ( 22 ) , with the most common being apoE Sendai ( 32 ) . This raises the possibility of divergent effects of macrophage expression of this protein Representative PAS (upper panels) and Jones (lower panels) stains of kidney sections from apoE Ϫ / Ϫ recipient mice 8 weeks after BMT. a consequence, is effi ciently released by the macrophage. Interestingly, expression of a Sendai-like mutation "repairs" the secretory blockade of apoE2. As LRP1 is also involved in macrophage infl ammation and signaling ( 16, 52, 53 ) , the impaired interaction of apoE Sendai with LRP1 may also have functional consequences involving lesion infl ammation. Clinical symptoms of LPG vary from mild proteinuria to nephrotic syndrome and chronic renal failure ( 20, 54, 55 ) . LPG recurs in transplanted kidneys, implicating systemic rather than renal factors in the development of the disease ( 21, 56 ) . LPG patients present elevated apoE serum levels and often an abnormal lipid profi le compared with control subjects (24) (25) (26) . Interestingly, LPG patients carrying apoE Sendai have higher apoE and cholesterol levels compared with asymptomatic apoE Sendai carriers ( 26 ) . Our experimental model suggests that: 1 ) apoE Sendai expressed by macrophages does not convey a particular risk for LPG; 2 ) low levels of apoE Sendai alone are not suffi cient to cause LPG, while they decrease serum cholesterol levels and atherosclerosis; 3 ) higher levels of apoE Sendai reduce atherosclerosis even when they do not affect serum cholesterol levels; 4 ) higher levels of apoE Sendai during hyperlipidemia cause a renal phenotype similar to LPG; and 5 ) expression of apoE Sendai causes LPG via glomerular lipid deposition, not macrophage infi ltration.
We conclude that macrophage apoE Sendai inhibits atherosclerosis while promoting renal disease, two pathologies that share etiologic factors and treatment approaches. ( 15 ) . Atherogenesis is infl uenced by macrophage expression of apoE ( 11 ) , the effects of which manifest as: 1 ) secretion into the circulation and association with lipoproteins to mediate their hepatic uptake ( 3, 6 ); and 2 ) modulation of the macrophage infl ammatory response in the atheroma ( 16, 17 ) . Our data show that macrophage apoE Sendai is highly athero-protective when compared with macrophage apoE2 and results in decreased lesion size, by 32 and 18% in apoE Ϫ / Ϫ and DKO recipient mice, respectively.
In addition, apoE Sendai exerts a local anti-infl ammatory effect in the atheroma with reduced lesional accumulation of infl ammatory monocytes (Ly6C-or CCR2-positive cells) when compared with apoE2. This effect may explain the changes in lesion size even in the absence of cholesterol differences. Although macrophage apoE Sendai is considered an apoE2 mutant (due to a similar charge), it was, in fact, as athero-protective as apoE3. It was previously reported that bone marrow-derived monocytes differentiate into M2 and eventually M1 macrophages. Despite differences in lesional monocyte composition, we could not detect differences in M1/M2 macrophages among any of the groups. We studied lesion development at an early stage (20 weeks), when plaque macrophages are mainly M2. Differentiation into M1 macrophages in the lesion becomes dominant in more advanced stages (>55 weeks) ( 19 ) .
apoE Sendai has functional characteristics distinct from other apoE mutants, such as increased binding to HSPGs and reduced binding to the LDLR ( 30 ) . LRP1 is another lipoprotein receptor involved in apoE metabolism. We previously reported that apoE-LRP1 interactions in macrophages control the rate of apoE secretion ( 51 ) . We show that apoE Sendai has impaired binding to LRP1 and, as 
